New Data from Clene’s RESCUE-ALS Study to be Presented at 2022 ENCALS Meeting
SALT LAKE CITY, June 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the presentation of new data from the company’s Phase 2 RESCUE-ALS study at the European Network to Cure ALS (ENCALS) Meeting 2022 taking place June 1-3 in Edinburgh, Scotland.
Sangri Today
Sangri Today is a Weekly Bilingual Newspaper and website of news and current affairs that publishes news reports from various places, from general reports.
Advertisement
Want to get your story featured as above? click here!
Advertisement
Want to get your story featured as above? click here!
